Warhound Launches at $1.2B Valuation to Solve U.S. Military's Working Dog Supply Crisis

For U.S. military units and law enforcement agencies, the search for reliable working dogs is becoming a supply chain problem with significant financial and operational implications. As the domestic pool of fit canines shrinks, the nation is increasingly dependent on foreign sources, a dynamic that has prompted the launch of Warhound, a new venture valued at $1.2 billion. The company has secured $200 million in funding from major investors, including Sequoia, 8VC, Corner Ventures, and In-Q-Tel, the latter being a venture firm with ties to the CIA and other U.S. intelligence agencies. This capital injection signals a shift toward treating working dogs not just as assets, but as a high-stakes engineering challenge.

The genesis of the company traces back to a conversation between Ben Lamm of Colossal Biosciences and Anduril co-founder Palmer Luckey at a conference approximately one year ago. Luckey raised concerns about the state of military working dogs, sparking Lamm’s research into canine breeding. Lamm discovered that a significant number of dogs fail training due to inherited health issues, such as poor vision, cancer predispositions, hip dysplasia, and muscle atrophy. This realization formed the basis for Warhound’s mission: to engineer dogs specifically for demanding missions.

The market gap is stark. According to the company’s launch announcement, more than 80 percent of the U.S. military’s working dogs are sourced from Europe. Of those imported animals, fewer than half are deemed fit for service. This reliance on foreign supply chains exposes the U.S. to logistical risks and quality inconsistencies. Warhound intends to disrupt this status quo by creating a domestic supply of genetically optimized dogs, reducing the wait times and health risks associated with traditional breeding methods.

Technologically, the venture is a joint effort between Colossal Biosciences and Anduril. Lamm’s team has established a biobank using cell lines from top-performing breeds, specifically the Belgian Malinois and the German Shepherd. The plan involves editing these genes to enhance traits like speed, agility, and olfactory sensitivity for tasks such as bomb detection, while simultaneously removing genetic markers associated with health decline. Colossal, known for its de-extinction projects like the woolly mammoth and dodo, will license its gene-cloning technology to Warhound and hold equity in the business.

While Colossal handles the biological engineering, Anduril will provide the technological hardware and software. This includes protective vests and goggles equipped with data sensors. These devices are designed to improve situational awareness for both the dogs and their human handlers. Lamm described the concept as adding safety and performance capabilities “on top of the dog, not in the dog,” ensuring that the animals are better protected in the line of duty. Luckey serves as a partner in the venture but does not hold equity, according to Lamm.

The timeline for bringing these animals to market is aggressive. The first batch of genetically modified dogs is currently in the cloning and incubation phase, with births expected in early 2027. The company aims to have the animals in service within two years. Viagen, another entity under the Colossal umbrella, will handle the cloning process, leveraging a technology that Lamm noted has a high success rate, currently used in endangered species protection programs.

Monetization and government approval are next on the agenda. While pricing has not yet been determined, Warhound expects to sell directly to the Department of Defense, military service groups, police forces, and first responders. Lamm indicated that the company has already briefed various government bodies. To address public concerns regarding the welfare of genetically enhanced animals, Warhound is working under the guidance of the American Humane Society to certify its training program. The society stated it looks forward to ensuring the animals are treated humanely, a critical step for a company entering a market where public sentiment often influences adoption rates.

Ultimately, this launch represents a convergence of biotechnology, defense hardware, and venture capital. By addressing the dwindling supply of fit working dogs, Warhound is positioning itself to become a central player in national security infrastructure. The next two years will determine whether this $1.2 billion valuation translates into operational success on the front lines.